Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 376

Sort by

Sort Order Select

Journal Articles

Induction chemotherapy and molecular MRD influence outcomes in KMT2A -rearranged AML

Blood (2025) 146 (15): 1862–1867.

https://doi.org/10.1182/blood.2025029556

Published: 2025

Includes: Supplemental data

Journal Articles

Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma

Blood (2024) 144 (24): 2490–2502.

https://doi.org/10.1182/blood.2024024381

Published: 2024

Includes: Supplemental data

Journal Articles

Identification of Hepatic-like Erythropoietin with Enhanced Activity As a New Cause of Hereditary and Acquired Erythrocytosis

Laurent Martin, Darko Maric, Salam Idriss, Marine Delamare, Amandine Le Roy, Nada Maaziz, Amandine Caillaud, Karim Si-Tayeb, Florence Robriquet, Marion Lenglet, Lucie Erceau, Christine Bellanné-Chantelot, Isabelle Plo, Bernard Aral, Céline Garrec, Fabrice Airaud, Clara Gianfermi, Vincent Antunes, Anna Keppner, Sarah Mathilda Vincent, Alexis Desfontaine, Nina Modé, Fabien Laporte, Anne Gaignerie, Caroline Chariau, Isabelle Leray, Coline Rogue, Laurent David, Richard Redon, Stephane Bezieau, Lamisse Mansour, Frederic Galacteros, Thibault Maillet, Marlène Pasquet, Pierre Cougoul, Anne-Marie Nloga, Claude Gardin, Corinne Guitton, Viviane Dubruille, Vannina Giacobbi-Milet, Thierry Leblanc, Zuhre Kaya, Denis Semama, Chloe James, Serge Carillo, Marlène Ochmann, Anders Waage, Erwan Mortier, Mike Maillasson, Agnès Quéméner, Holger Cario, Radek C. Skoda, Yaël Zermati, David Hoogewijs, Alexandre Marchand, Francois Girodon, Betty Gardie

Blood (2024) 144 (Supplement 2): LBA-2.

https://doi.org/10.1182/blood-2024-213000

Published: 2024

Journal Articles

In Vitro and In Vivo Characterization of Axicabtagene Ciloleucel Identifies Features Associated with Treatment Resistance in Patients, Including a Dysfunctional CD8+ T Cell State Characterized By Overexpression of GATA3 Transcript

Blood (2024) 144 (Supplement 1): 7159.

https://doi.org/10.1182/blood-2024-209570

Published: 2024

Journal Articles

Rker-050, a Modified Activin Receptor Type Iia Ligand Trap, Regulates Osteogenic Lineage, Complementing the Erythroid Response and Rebalancing the Osteo-Hematopoietic Niche

Vamsee D Myneni, Mike Dills, Savanna Macaluso, Radina Todorova, Lorena Lerner, Jasbir Seehra, Jenn Lachey, Samuel Cadena

Blood (2024) 144 (Supplement 1): 5660.

https://doi.org/10.1182/blood-2024-208738

Published: 2024

Journal Articles

Activin a Inhibition Impaired Human AML Cell Engraftment and Extended Survival in Immunodeficient Mice

Blake Moses, Ashlyn Wheeler, Mike Dills, Tyler Daman, Rosa Grenha, Lorena Lerner, Jasbir Seehra, Jenn Lachey, Samuel Cadena

Blood (2024) 144 (Supplement 1): 5658.

https://doi.org/10.1182/blood-2024-208031

Published: 2024

Journal Articles

Selinexor, Venetoclax, and Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)

Blood (2024) 144 (Supplement 1): 7049.

https://doi.org/10.1182/blood-2024-193966

Published: 2024

Journal Articles

Rituximab Responsive Cytopenia Following Allogeneic Stem Cell Transplantation

John Murray, Joanita Kintu, Adrian Bloor, Mike Dennis, Anna Z Castleton, Mark Williams, David Kaye, James Cavet, Samar Kulkarni

Blood (2024) 144 (Supplement 1): 7400.

https://doi.org/10.1182/blood-2024-211445

Published: 2024

Journal Articles

A Novel, Universal Targeting Receptor-Adaptor CAR Platform Demonstrates Versatile, Flexible, and Controlled Tumor Inhibition in an Ipsc-Derived T-Cell

Andrew Devaney, Jill Carton, Hunter Hoffman, Hillary J. Millar, David Walker, John Wheeler, Mike Miller, Chris Dower, Barry Morse, Hy Levitsky, Michael Naso

Blood (2024) 144 (Supplement 1): 7181.

https://doi.org/10.1182/blood-2024-210141

Published: 2024

Journal Articles

Timely Use of Donor Lymphocyte Infusion (DLI) Improves Allogeneic Transplant Outcomes

Samar Kulkarni, Adrian Bloor, Mike Dennis, Anna Z Castleton, Mark Williams, Noel Collins, John Murray

Blood (2024) 144 (Supplement 1): 7399.

https://doi.org/10.1182/blood-2024-211329

Published: 2024

Journal Articles

Predictors of Successful Allogeneic Stem Cell Donor Collection

Samar Kulkarni, Adrian Bloor, Mike Dennis, Angie Leather, Rose Brewster, Helen Morgan, Laura Roger, Amy Cadogan, Alethea Braden, Loredana Oraka, Ellen Lidstone, Sarah Wilson, John Murray, Jo Tomlins, Ahmed Abdulgawad, Mohd Mamat, James Cavet, Anna Z Castleton

Blood (2024) 144 (Supplement 1): 7270.

https://doi.org/10.1182/blood-2024-211181

Published: 2024

Journal Articles

Use of Natural Language Processing to Identify Myeloid/Lymphoid Neoplasm Patients with Fibroblast Growth Factor Receptor 1 Alterations

Sumit Verma, Mike Blecker, Thomas Edwards, Meg Richards, Shreekant V. Parasuraman, Evan M. Braunstein, Pankit Vachhani

Blood (2024) 144 (Supplement 1): 7900.

https://doi.org/10.1182/blood-2024-199205

Published: 2024

Journal Articles

Fungal Blood Stream Infections (BSI) in Hematology-Oncology Patients Have Worse Outcomes Than Solid Tumour Patients

Vismay Deshani, H Hemat, Adrian Bloor, Mike Dennis, Alex Peel, Adam Jeans, Anna Z Castleton, Emma Searle, Daniel H Wiseman, Mark Williams, Richard Chasty, Ahmed Abdulgawad, Tim Somervaille, John Murray, Jane Robertson, James Cavet, Samar Kulkarni

Blood (2024) 144 (Supplement 1): 7897.

https://doi.org/10.1182/blood-2024-198526

Published: 2024

Journal Articles

R289, a Dual Irak 1/4 Inhibitor, in Patients with Relapsed/Refractory (R/R) Lower-Risk Myelodysplastic Syndrome (LR-MDS): Initial Results from a Phase 1b Study

Guillermo Garcia-Manero, Yazan F Madanat, Mikkael A. Sekeres, Hetty E. Carraway, Mike Cusnir, James McCloskey, Kiran Naqvi, Gary J. Schiller, Lucy Yan, Toufigh Gordi, Lisa Rojkjaer, Lewis R. Silverman

Blood (2024) 144 (Supplement 1): 4595.

https://doi.org/10.1182/blood-2024-206096

Published: 2024

Journal Articles

Prediction Model to Evaluate Engraftment Kinetics Following Stem Cell Transplantation

Samar Kulkarni, Adrian Bloor, Mike Dennis, Anna Z Castleton, Mark Williams, Ahmed Abdulgawad, Tim Somervaille, Daniel H Wiseman, Vismay Deshani, Emma Searle, Angie Leather, John Murray, Sally Pickering, James Cavet

Blood (2024) 144 (Supplement 1): 3496.

https://doi.org/10.1182/blood-2024-211021

Published: 2024

Journal Articles

Multiomic Discovery of Neopeptides from Non-Canonical ORFs on SF3B1 Mutation-Driven lncRNAs in Leukemia

Supriyo Bhattacharya, Mike Fernandez, Yiming Wu, Meiling Jin, Lili Wang

Blood (2024) 144 (Supplement 1): 1061.

https://doi.org/10.1182/blood-2024-208361

Published: 2024

Journal Articles

Impact of Cytogenetics, Induction Chemotherapy and MRD on Outcomes of Intensively Treated AML with KMT2A Rearrangements - Experience from UK NCRI AML17 and AML19

Blood (2024) 144 (Supplement 1): 845.

https://doi.org/10.1182/blood-2024-201097

Published: 2024

Journal Articles

SF3B1 Mutation Drives Loss of Y Chromosome in Chronic Lymphocytic Leukemia

Mike Fernandez, Lei Yu, Qiong Jia, Xuesong Wang, Kevyn Hart, Zhenyu Jia, Ren-Jang Lin, Lili Wang

Blood (2024) 144 (Supplement 1): 46.

https://doi.org/10.1182/blood-2024-208209

Published: 2024

Journal Articles

A Randomised Comparison of CPX-351 Versus Standard Daunorubicin and Cytarabine Plus Fractionated Gemtuzumab Ozogamicin in Older Adults with AML without Adverse Risk Cytogenetics: Results of the NCRI AML18 Trial

Blood (2024) 144 (Supplement 1): 59.

https://doi.org/10.1182/blood-2024-200027

Published: 2024

Journal Articles

Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Blood (2024) 144 (Supplement 1): 353.

https://doi.org/10.1182/blood-2024-198326

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Induction chemotherapy and molecular MRD influence outcomes in KMT2A -rearranged AML

Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma

Identification of Hepatic-like Erythropoietin with Enhanced Activity As a New Cause of Hereditary and Acquired Erythrocytosis

In Vitro and In Vivo Characterization of Axicabtagene Ciloleucel Identifies Features Associated with Treatment Resistance in Patients, Including a Dysfunctional CD8+ T Cell State Characterized By Overexpression of GATA3 Transcript

Rker-050, a Modified Activin Receptor Type Iia Ligand Trap, Regulates Osteogenic Lineage, Complementing the Erythroid Response and Rebalancing the Osteo-Hematopoietic Niche

Activin a Inhibition Impaired Human AML Cell Engraftment and Extended Survival in Immunodeficient Mice

Selinexor, Venetoclax, and Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)

Rituximab Responsive Cytopenia Following Allogeneic Stem Cell Transplantation

A Novel, Universal Targeting Receptor-Adaptor CAR Platform Demonstrates Versatile, Flexible, and Controlled Tumor Inhibition in an Ipsc-Derived T-Cell

Timely Use of Donor Lymphocyte Infusion (DLI) Improves Allogeneic Transplant Outcomes

Predictors of Successful Allogeneic Stem Cell Donor Collection

Use of Natural Language Processing to Identify Myeloid/Lymphoid Neoplasm Patients with Fibroblast Growth Factor Receptor 1 Alterations

Fungal Blood Stream Infections (BSI) in Hematology-Oncology Patients Have Worse Outcomes Than Solid Tumour Patients

R289, a Dual Irak 1/4 Inhibitor, in Patients with Relapsed/Refractory (R/R) Lower-Risk Myelodysplastic Syndrome (LR-MDS): Initial Results from a Phase 1b Study

Prediction Model to Evaluate Engraftment Kinetics Following Stem Cell Transplantation

Multiomic Discovery of Neopeptides from Non-Canonical ORFs on SF3B1 Mutation-Driven lncRNAs in Leukemia

Impact of Cytogenetics, Induction Chemotherapy and MRD on Outcomes of Intensively Treated AML with KMT2A Rearrangements - Experience from UK NCRI AML17 and AML19

SF3B1 Mutation Drives Loss of Y Chromosome in Chronic Lymphocytic Leukemia

A Randomised Comparison of CPX-351 Versus Standard Daunorubicin and Cytarabine Plus Fractionated Gemtuzumab Ozogamicin in Older Adults with AML without Adverse Risk Cytogenetics: Results of the NCRI AML18 Trial

Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only